Abbott Laboratories (ABT) Akcie Kurz
Abbott Laboratories Kurz
Za posledních 19 let vzrostly tržby Abbott Laboratories o 3,6 % ročně a dosáhly 44,33 Mld. USD. Zisk na akcii rostl o 6,6 % ročně za posledních 19 let. U Abbott Laboratories je čistá marže 14,7 % dolů oproti 16,4 % před několika lety. Při dnešní ceně vychází dividendový výnos zhruba na 2,30 %. Výplatní poměr je kolem 63 % zisku. Dividenda rostla o 3,8 % ročně za posledních 19 let. Konsenzuální 12měsíční cílová cena pro Abbott Laboratories je 121,00 USD, asi nad cenu o 17,9 %. Z 32 analytiků jich 26 doporučuje nákup — celkový konsenzus je Koupit.
Cena akcie Abbott Laboratories
Tato data přes Eulerpool API
100 000 požadavků/měs. zdarma · bez karty
Obchodní model Abbott Laboratories a analýza akcií
Nejčastější otázky týkající se akcie Abbott Laboratories
Abbott Laboratories is a renowned healthcare company with a strong business model focused on providing a diverse range of medical products, diagnostics, nutritional supplements, and pharmaceuticals. By combining technological advancements with innovative research, Abbott aims to enhance the quality of life for individuals worldwide. With a comprehensive portfolio spanning diverse healthcare sectors, including diagnostics, nutrition, diabetes care, medical devices, and branded generic pharmaceuticals, Abbott Laboratories strives to improve patient outcomes and deliver sustainable growth. Through its commitment to scientific excellence and dedication to meeting evolving healthcare needs, Abbott Laboratories has established itself as a trusted leader in the global healthcare industry.
Abbott Laboratories is primarily active in the healthcare industry.
The main competitors of Abbott Laboratories in the market are Johnson & Johnson, Pfizer, and Roche Holding AG.
Abbott Laboratories is a renowned American healthcare company, known for providing a diverse range of medical, pharmaceutical, and nutritional products. Founded in 1888 by Dr. Wallace C. Abbott, the company initially focused on producing pharmaceuticals, including the widely successful alkaloid-based pain reliever, Abbott's ABC Liniment. Over the years, Abbott Laboratories has expanded its portfolio, venturing into areas such as diagnostics, medical devices, and nutrition. The company's commitment to innovation is evident through breakthroughs like the development of the first HIV blood-screening test. Today, Abbott Laboratories continues to play a crucial role in improving health outcomes worldwide, with its cutting-edge technology and a focus on delivering quality healthcare solutions.
Abbott Laboratories has achieved several significant milestones throughout its history. One major milestone was the development and commercialization of the first-ever HIV blood screening test, which greatly contributed to safer transfusions and the prevention of the spread of HIV. Additionally, Abbott Laboratories introduced breakthrough medical devices, such as the FreeStyle® Libre system, a continuous glucose monitoring system for diabetes management. The company also played a crucial role in the fight against COVID-19 by developing rapid diagnostic tests for the virus. Furthermore, Abbott Laboratories has consistently been recognized for its commitment to innovation and sustainability, making it a leading healthcare company globally.
Abbott Laboratories is primarily present in multiple countries and regions worldwide. The company operates in more than 160 countries, including the United States, Canada, Europe, Asia-Pacific, Latin America, and the Middle East. With a strong global footprint, Abbott Laboratories has established itself as a leading healthcare company in various markets, delivering innovative medical products, diagnostics, nutritionals, and pharmaceuticals to improve people's health and well-being.
Abbott Laboratories is committed to its core values of putting patients first, serving customers with innovative solutions, and operating with integrity in all aspects of its business. The company's corporate philosophy centers around improving life through the development of groundbreaking technologies and products. Abbott Laboratories prides itself on its dedication to delivering reliable healthcare solutions, fostering collaboration with healthcare professionals, and investing in research and development to address unmet medical needs. With a focus on providing high-quality and accessible healthcare options, Abbott Laboratories strives to create positive impacts in communities worldwide through its diverse portfolio of medical devices, diagnostics, nutrition, and pharmaceutical products.
Analytici aktuálně stanovují průměrnou cílovou cenu 123,64 USD pro akcii Abbott Laboratories (medián: 121,00 USD), tedy +16,4 % vůči poslední ceně. Konsensus vychází z 32 hodnocení analytiků.
32 analytiků aktuálně hodnotí akcii Abbott Laboratories: 26 doporučuje koupit, 6 držet a 0 prodat. Pro rok 2026 analytici očekávají u Abbott Laboratories tržby 49,99 Mld. USD a zisk na akcii 5,52 USD.
Při aktuálním kurzu se akcie Abbott Laboratories obchoduje za 91,92 EUR (102,64 USD).
Akcie Abbott Laboratories (ABT) je kótována na 9 burzách, mimo jiné: NYSE (ABT), London (0Q15.L), SIX (Zürich) (ABT.SW), XETRA (ABL.DE), Frankfurt (ABL.F), München (ABL.MU), Düsseldorf (ABL.DU), Hamburg (ABL.HM).
Abbott Laboratories is a global company specializing in the development, manufacturing, and marketing of health products and services. Its business model is divided into different divisions that focus on the needs of patients, doctors, and healthcare systems. The divisions of Abbott Laboratories include Diagnostics, Medical Devices, Nutrition, and Pharmaceutical. The company aims to continuously develop innovative technologies and products to improve healthcare, and it offers a wide range of services and support programs for patients. Abbott Laboratories has established a strong market position and global presence in over 160 countries since its establishment in 1888. It also pursues a successful acquisition strategy to expand its product portfolio, such as the acquisition of St. Jude Medical in 2017 to enhance its cardiovascular products and services. Overall, Abbott Laboratories aims to improve healthcare and meet the needs of patients, doctors, and healthcare systems through its comprehensive strategy focused on developing innovative products, expanding into new markets, and increasing efficiency.
Tržby očekávané za Abbott Laboratories činí 49,99 Mld. USD. Tato hodnota je založena na aktuálních finančních údajích a odráží výkonnost společnosti.
Zisk očekávané za Abbott Laboratories činí 9,64 Mld. USD. Čistý zisk odráží ziskovost společnosti po odečtení všech nákladů.
Poměr ceny k zisku (P/E) Abbott Laboratories je aktuálně 18,59. Poměr P/E porovnává aktuální cenu akcie se ziskem na akcii a pomáhá investorům posoudit ocenění akcie Abbott Laboratories.
Poměr ceny k tržbám (P/S) Abbott Laboratories je aktuálně 3,59. Poměr P/S porovnává tržní kapitalizaci s ročními tržbami a slouží jako metrika ocenění akcie Abbott Laboratories.
Score kvality pro Abbott Laboratories je 6/10.
ISIN Abbott Laboratories je US0028241000. ISIN (International Securities Identification Number) je celosvětově jedinečný identifikátor cenných papírů.
WKN Abbott Laboratories je 850103. WKN (Wertpapierkennnummer) je šestimístný německý identifikační kód cenného papíru.
Ticker Abbott Laboratories je ABT. Symbol tickeru se používá k obchodování akcií Abbott Laboratories na burze.
Abbott Laboratories akcie
Abbott Laboratories Peer Group
Abbott Laboratories Ticker
Abbott Laboratories FIGI
Všechny fundamentální údaje o Abbott Laboratories v podrobné analýze
Naše analýzy akcií společnosti Abbott Laboratories zahrnují důležité finanční ukazatele jako obrat, zisk, P/E poměr, P/S poměr, EBIT, stejně jako informace o dividendách. Dále zkoumáme aspekty jako akcie, tržní kapitalizaci, dluhy, vlastní kapitál a závazky společnosti Abbott Laboratories. Pokud hledáte podrobnější informace o těchto tématech, nabízíme vám na našich podstránkách rozsáhlé analýzy: